Comparison of outcomes of tyrosine kinase inhibitor in first- or second-line therapy for advanced non-small-cell lung cancer patients with sensitive EGFR mutations

Direct comparisons between the use of first- and second-line EGFR tyrosine kinase inhibitor (TKI) in patients with sensitive EGFR mutations are limited. A total of 264 advanced non-small-cell lung cancer (NSCLC) patients with sensitive mutations received EGFR TKI therapy as the first-line therapy, a...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Jianlin, Zhang, Xueyan, Yang, Haitang, Ding, Guozheng, Jin, Bo, Lou, Yuqing, Zhang, Yanwei, Wang, Huimin, Han, Baohui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356566/
https://www.ncbi.nlm.nih.gov/pubmed/27637087
http://dx.doi.org/10.18632/oncotarget.12035

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356566/
https://www.ncbi.nlm.nih.gov/pubmed/27637087
http://dx.doi.org/10.18632/oncotarget.12035

Ejemplares similares